PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50120C00001 — ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION

ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION is a federal NONE award for Department of Health and Human Services (HHS) held by PARATEK PHARMACEUTICALS, INC.. Estimated value $265.3M ($108.7M obligated). Current period of performance ends Dec 17, 2029. Last award drew 4 bidders. Place of performance: BOSTON, MA. Related solicitation 19-100-SOL-00011.

$265.3M
Estimated Value
$108.7M
Obligated
Dec 17, 2029
PoP End / Expires
4
Bidders (last award)
More in SCOUT — score this to your firm →See related expiring contracts →

Analysis

Public

PARATEK PHARMACEUTICALS, INC. holds $40.7M across 2 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 4 offers. Set-aside status: NONE. Recompete timing centers on the Dec 17, 2029 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract number75A50120C00001
AgencyDepartment of Health and Human Services (HHS)
IncumbentPARATEK PHARMACEUTICALS, INC.
UEID5KEFN62CJ97
NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSC6505
Place of performanceBOSTON, MA
Related solicitation19-100-SOL-00011
PoP end (current)Dec 17, 2029
Obligated$108.7M

ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION

Recompete timing

Public
Expiring in 1222 days

Current PoP ends Dec 17, 2029 (1222 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Jun 17, 2028.

Track recompete timing in SCOUT →

Incumbent footprint

Public record

PARATEK PHARMACEUTICALS, INC.$40.7M obligated across 2 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)
Department of Health and Human Services (HHS)$40.7M · 100% of firm total
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Score this to your firm — $90 Pilot →

Live Demand-Fit + Displacement scoring, alerts on verdict flips, and watchlists. 90 days · $90 · no annual contract · cancel anytime

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open PARATEK PHARMACEUTICALS, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75A50120C00001?

75A50120C00001 (ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION) is a Department of Health and Human Services (HHS) award with an estimated value of $265.3M, currently held by PARATEK PHARMACEUTICALS, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75A50120C00001?

PARATEK PHARMACEUTICALS, INC. is the incumbent with $40.7M across 2 related awards in SCOUT’s public footprint. The current period of performance ends Dec 17, 2029.

When does 75A50120C00001 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 17, 2029. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50120C00001